Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Drug Profile

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase II Colorectal cancer; Gastric cancer; Renal cell carcinoma
  • Phase I/II Solid tumours
  • Phase I Glioblastoma
  • No development reported Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Aug 2018 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans the REACTION phase I/II trial for Oesophageal and Gastric cancer (Combination therapy) in USA , (NCT03610711)
  • 31 Jul 2018 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Bristol-Myers Squibb plan a phase II trial for Solid tumours (Combination therapy, Second-line therapy or greater) in USA (NCT03607890)
  • 25 May 2018 Bristol-Myers Squibb initiates a phase I/II trial for Solid tumours (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT03459222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top